151 related articles for article (PubMed ID: 19260349)
1. [Profile of garenoxacin as respiratory quinolones (discussion)].
Yamaguchi K
Jpn J Antibiot; 2008 Oct; 61(5):289-302. PubMed ID: 19260349
[No Abstract] [Full Text] [Related]
2. [Pharmacological properties and clinical efficacy of garenoxacin mesilate hydrate (Geninax Tablet 200 mg), a quinolone antimicrobial].
Tsuda H
Nihon Yakurigaku Zasshi; 2008 Aug; 132(2):111-8. PubMed ID: 18689961
[No Abstract] [Full Text] [Related]
3. [Clinical position of sitafloxacin in outpatient chemotherapy. (discussion)].
Niki Y; Aoki N; Suzuki K; Matsumoto T
Jpn J Antibiot; 2009 Jun; 62(3):179-93. PubMed ID: 19882979
[No Abstract] [Full Text] [Related]
4. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation].
Mikamo H; Tanaka K; Watanabe K
Jpn J Antibiot; 2007 Dec; 60(6):335-43. PubMed ID: 18447205
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies of garenoxacin.
Takagi H; Tanaka K; Tsuda H; Kobayashi H
Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
[TBL] [Abstract][Full Text] [Related]
6. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
Blondeau JM; Tillotson G
Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
[TBL] [Abstract][Full Text] [Related]
7. [Recent drug administration methods for respiratory infections].
Matsumoto K; Iwagaki A
Nihon Naika Gakkai Zasshi; 1991 May; 80(5):675-80. PubMed ID: 1651973
[No Abstract] [Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
[TBL] [Abstract][Full Text] [Related]
9. [Role of oral fluoroquinolones in patients with respiratory diseases].
Ishida T
Kekkaku; 2003 Oct; 78(10):653-9. PubMed ID: 14621574
[TBL] [Abstract][Full Text] [Related]
10. Trials and tribulations of antibiotic development.
Lancet Infect Dis; 2008 Apr; 8(4):209. PubMed ID: 18353256
[No Abstract] [Full Text] [Related]
11. The newer fluoroquinolones.
Bolon MK
Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
[TBL] [Abstract][Full Text] [Related]
12. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
13. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development.
Simoens S; Verhaegen J; Laekeman G; Peetermans WE
Int J Antimicrob Agents; 2005 Jul; 26(1):62-8. PubMed ID: 15963695
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
Ohsaki Y; Morita K; Takeda H; Kishino S; Okumura S; Fujiuchi S
Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
[TBL] [Abstract][Full Text] [Related]
15. Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G; Rossi V; Salvatori E; Mirelis B
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
[TBL] [Abstract][Full Text] [Related]
16. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
17. [Significant role of penem antibiotics: focused on faropenem (discussion)].
Saito A; Moritono S; Arata J; Saito A
Jpn J Antibiot; 1997 Jul; 50(7):579-90. PubMed ID: 9743904
[No Abstract] [Full Text] [Related]
18. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
19. Delafloxacin for the treatment of respiratory and skin infections.
Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
